IDO1 and melanoma: In addition, a phase II trial reported that a combination of IDO inhibitor indoximod plus anti-PD1/PDL-1 antibodies pembrolizumab, nivolumab, and ipilimumab resulted in increased progression-free survival and a better response in patients with advanced melanoma (254).